WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Stock Ownership - Who owns Enliven Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Enliven Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Joseph P. LyssikatosCHIEF SCIENTIFIC OFFICER2025-10-2012,500$22.08
$276.03kSell
Samuel KintzPRESIDENT AND CEO2025-10-1712,500$21.33
$266.65kSell
Anish PatelCHIEF OPERATING OFFICER2025-10-076,667$20.10
$133.99kSell
Benjamin HohlCHIEF FINANCIAL OFFICER2025-09-293,250$2.48
$8.06kBuy
Benjamin HohlCHIEF FINANCIAL OFFICER2025-09-293,250$20.40
$66.29kSell
Samuel KintzPRESIDENT AND CEO2025-09-263,700$20.06
$74.23kSell
Joseph P. LyssikatosCHIEF SCIENTIFIC OFFICER2025-09-264,000$20.25
$81.00kSell
Joseph P. LyssikatosCHIEF SCIENTIFIC OFFICER2025-09-231,500$20.03
$30.05kSell
Samuel KintzPRESIDENT AND CEO2025-09-232,800$20.03
$56.08kSell
Samuel KintzPRESIDENT AND CEO2025-09-191,000$20.25
$20.25kSell

1 of 11

ELVN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ELVN insiders and whales buy or sell their stock.

ELVN Shareholders

What type of owners hold Enliven Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC17.21%10,195,751$230.93MInsider
David P. Bonita14.18%8,398,136$190.22MInsider
5am Partners VI LLC13.75%8,142,154$184.42MInsider
Orbimed Advisors LLC13.44%7,959,538$180.28MInstitution
Rishi Gupta13.42%7,951,463$180.10MInsider
Fmr LLC12.76%7,559,901$171.23MInstitution
Commodore Capital LP7.92%4,692,809$106.29MInstitution
Vr Adviser LLC6.80%4,026,331$91.20MInstitution
Fairmount Funds Management LLC6.27%3,711,444$84.06MInstitution
Ra Capital Management LP6.04%3,576,813$81.01MInsider

1 of 3

ELVN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ELVN49.50%50.50%Net SellingNet Selling
CDTX62.76%37.24%Net BuyingNet Selling
IMNM91.25%7.71%Net BuyingNet Buying
UPB72.85%27.15%
MAZE83.04%16.96%Net SellingNet Selling
View Top Biotech Stocks

Enliven Therapeutics Stock Ownership FAQ

Who owns Enliven Therapeutics?

Enliven Therapeutics (NASDAQ: ELVN) is owned by 100.34% institutional shareholders, 102.36% Enliven Therapeutics insiders, and 0.00% retail investors. Orbimed Advisors LLC is the largest individual Enliven Therapeutics shareholder, owning 10.20M shares representing 17.21% of the company. Orbimed Advisors LLC's Enliven Therapeutics shares are currently valued at $244.39M.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.